Clinical trial
AV650 Drug-Drug Interaction Study
NCT00456560 · Avigen, Industry · Completed
Key facts
| NCT number | NCT00456560 |
|---|---|
| Title | AV650 Drug-Drug Interaction Study |
| Official title | A Phase I, Randomized, Two-Period, Single-Center Study to Assess the Effect of CYP2D6 and CYP2C19 Inhibitors on a Single Oral Dose of AV650 (300 mg) in Healthy Subjects |
| Lead sponsor | Avigen, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Drug |
| Interventions | AV650, Fluvoxamine, Paroxetine |
| Enrollment | 30 |
| Start date | Apr 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Apr 5, 2007 |
| Last update posted | Sep 17, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: